Még nem toboroz
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL-M07D1) vs. Platinum-based Chemotherapy in Patients with HER2-expressing metastatic urothelial cancer with disease progression on or after anti-PD-(L)1-based therapy
2026-527617-29-00· 3. fázis· Forrás
Még nem toboroz
Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer.
NCT07717450· 3. fázis· Forrás
Toboroz
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295· 3. fázis· Forrás
Toboroz
Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma
2024-519208-29-00· 2. fázis· Forrás
Toboroz
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
2024-516906-47-00· 2/3. fázis· Forrás
Toboroz
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
2025-520555-89-00· 3. fázis· Forrás
Toboroz
Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.
NCT07192068· 2. fázis· Forrás
Toboroz
Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients
NCT06529718· 2. fázis· Forrás
Toboroz
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
NCT07022483· 3. fázis· Forrás
Toboroz
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· 2/3. fázis· Forrás
Toboroz
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719· 3. fázis· Forrás
Toboroz
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
NCT06680596· 2. fázis· Forrás
Toboroz
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· 3. fázis· Forrás
Toboroz
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
NCT06625970· 3. fázis· Forrás
Toboroz
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112· 3. fázis· Forrás
Fut, nem toboroz
Phase 2/3 Randomized Study of INBRX-106 Add-on to Pembrolizumab in First-Line PD-L1 CPS ≥20 R/M HNSCC (HexAgon-HN)
2024-515538-34-00· 2/3. fázis· Forrás
Toboroz
Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.
NCT06450314· 2. fázis· Forrás
Toboroz
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
NCT06078384· 2. fázis· Forrás
Toboroz
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
NCT06435429· 3. fázis· Forrás
Toboroz
Adjuvant Tebentafusp in High Risk Ocular Melanoma
NCT06246149· 3. fázis· Forrás
Toboroz
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· 3. fázis· Forrás
Fut, nem toboroz
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324· 3. fázis· Forrás
Toboroz
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
NCT06496581· 3. fázis· Forrás
Fut, nem toboroz
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180· 3. fázis· Forrás
Toboroz
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
NCT06195709· 3. fázis· Forrás
Toboroz
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729· 3. fázis· Forrás
Toboroz
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137· 3. fázis· Forrás
Toboroz
Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study
NCT05904119· 3. fázis· Forrás
Toboroz
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025· 2/3. fázis· Forrás
Toboroz
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624· 3. fázis· Forrás
Toboroz
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650· 3. fázis· Forrás
Fut, nem toboroz
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
NCT05476796· 2. fázis· Forrás
Fut, nem toboroz
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
NCT05617963· 2. fázis· Forrás
Toboroz
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
NCT05706129· 1/2. fázis· Forrás
Toboroz
Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations
NCT06511648· 2. fázis· Forrás
Fut, nem toboroz
Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors
NCT05219318· 3. fázis· Forrás
Fut, nem toboroz
Reduction of hormone therapy duration in women with hormonesensitive breast cancer at very low risk of metastatic recurrence
NCT05297617· 2. fázis· Forrás
Fut, nem toboroz
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299· 3. fázis· Forrás
Fut, nem toboroz
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
NCT05078047· 3. fázis· Forrás
Fut, nem toboroz
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· 3. fázis· Forrás
Fut, nem toboroz
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
NCT05038735· 3. fázis· Forrás
Toboroz
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483· 1. fázis· Forrás
Toboroz
Comparison of Cyclophosphamide and doxorubicin as a first line treatment in elderly patients with metastatic sarcoma
NCT04757337· 3. fázis· Forrás
Fut, nem toboroz
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
NCT04647526· 3. fázis· Forrás
Fut, nem toboroz
Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO33)
2024-516649-38-00· 3. fázis· Forrás
Toboroz
Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer
NCT03819101· 3. fázis· Forrás
Fut, nem toboroz
Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients
NCT03799835· 3. fázis· Forrás
Lezárult
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection
NCT03079011· 3. fázis· Forrás
Fut, nem toboroz
A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
NCT01952223· 3. fázis· Forrás
Fut, nem toboroz
Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
NCT01805271· 3. fázis· Forrás
Showing 50 of 52.